Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

被引：2
|
作者：
Eggermont, A. M. M. [1 ]
Chiarion-Sileni, V. [2 ]
Grob, J-J. [3 ]
Dummer, R. [4 ]
Wolchok, J. D. [5 ]
Schmidt, H. [6 ]
Hamid, O. [7 ]
Robert, C. [8 ]
Ascierto, P. A. [9 ]
Richards, J. M. [10 ]
Lebbe, C. [11 ,12 ]
Ferraresi, V. [13 ]
Smylie, M. [14 ]
Weber, J. S. [15 ]
Taitt, C. [16 ]
de Pril, V. [17 ]
de Schaetzen, G. [18 ,19 ]
Suciu, S. [18 ,19 ]
Testori, A. [20 ]
机构：
[1] Gustave Roussy Canc Campus Grand Paris, Oncol Surg, Villejuif, France
[2] IRCCS, IOV, Dept Dermatol, Melanoma Oncol Unit, Padua, Italy
[3] Aix Marseille Univ, Hop La Timone APHM, Dept Dermatol & Skin Canc, Marseille, France
[4] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland
[5] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 1275 York Ave, New York, NY 10021 USA
[6] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark
[7] Angeles Clin & Res Inst, Clin Res, Los Angeles, CA USA
[8] Gustave Roussy Canc Campus Grand Paris, Dermatol Unit, Villejuif, France
[9] Fdn G Pascale, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy
[10] Oncol Specialists SC, Div Hematol Oncol, Park Ridge, IL USA
[11] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,Dept Dermatol, Paris, France
[12] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,CIC Dept, Paris, France
[13] Ist Fisioterapici Ospitalieri, Dept Med Oncol, Rome, Italy
[14] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada
[15] H Lee Moffitt Canc Ctr & Res Inst, Dept Med, Tampa, FL USA
[16] Bristol Myers Squibb, Worldwide Med, Princeton, NJ USA
[17] Bristol Myers Squibb, Worldwide Med, Braine Lalleud, Belgium
[18] EORTC Headquarters, Melanoma Grp, Brussels, Belgium
[19] EORTC Headquarters, Melanoma Grp, Brussels, Belgium
[20] European Inst Oncol, Div Melanoma & Sarcomi Muscolocutanei, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw435.35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA2_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [31] RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF PAZOPANIB IN PATIENTS WITH ADVANCED/METASTATIC RENAL CELL CARCINOMA (MRCC): FINAL OVERALL SURVIVAL (OS) RESULTS
    Sternberg, C. N.
    Hawkins, R. E.
    Szczylik, C.
    Davis, I. D.
    Wagstaff, J.
    McCann, L.
    Chen, M.
    Rubin, S. D.
    ANNALS OF ONCOLOGY, 2010, 21 : 10 - 10
  • [32] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
    Eggermont, A. M. M.
    Kicinski, M.
    Blank, C. U.
    Mandala, M.
    Long, G. V.
    Atkinson, V. G.
    Dalle, S.
    Haydon, A. M.
    Meshcheryakov, A.
    Khattak, A.
    Carlino, M. S.
    Sandhu, S. K.
    Sarda, S. S. Puig
    Ascierto, P. A.
    Lorigan, P.
    Grebennik, D.
    Ibrahim, N.
    Marreaud, S. I.
    Suciu, S.
    Robert, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S912 - S913
  • [33] ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
    Wu, Yi-Long
    Herbst, Roy S.
    Mann, Helen
    Rukazenkov, Yuri
    Marotti, Marcelo
    Tsuboi, Masahiro
    CLINICAL LUNG CANCER, 2018, 19 (04) : E533 - E536
  • [34] Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial - Invited commentary
    Wanebo, HJ
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (01) : 77 - 79
  • [35] A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Harding, James J.
    Johnson, Matthew
    Palmer, Daniel H.
    Edeline, Julien
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Decaens, Thomas
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Galle, Peter R.
    Park, Joong-Won
    Yau, Thomas
    Begic, Damir
    Shen, Yun
    Neely, Jaclyn
    Sama, Ashwin Reddy
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA
    Coleman, Robert L.
    Oza, Amit
    Lorusso, Domenica
    Aghajanian, Carol
    Oaknin, Ana
    Dean, Andrew
    Colombo, Nicoletta
    Weberpals, Johanne
    Clamp, Andrew
    Scambia, Giovanni
    Leary, Alexandra
    Holloway, Robert
    Amenedo Gancedo, Margarita
    Fong, Peter
    Goh, Jeffrey
    O'Malley, David
    Goble, Sandra
    Maloney, Lara
    Ledermann, Jonathan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A3 - A5
  • [37] PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients
    Van der Graaf, Winette T. A.
    Blay, Jean-Yves
    Chawla, Sant P.
    Kim, Dong-Wan
    Binh Bui Nguyen
    Casali, Paolo Giovanni
    Schoffski, Patrick
    Aglietta, Massimo
    Staddon, Arthur P.
    Beppu, Yasuo
    Le Cesne, Axel
    Gelderblom, Hans
    Judson, Ian Robert
    Araki, Nobuhito
    Ouali, Monia
    Marreaud, Sandrine
    Hodge, Rachel
    Dewji, Mohamedraza
    Dei Tos, Angelo Paolo
    Hohenberger, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results
    Petrylak, D. P.
    Sternberg, C. N.
    Drakaki, A.
    de Wit, R.
    Nishiyama, H.
    Necchi, A.
    Castellano, D.
    Bamias, A.
    Chi, K. N.
    van der Heijden, M. S.
    Matsubara, N.
    Hussain, S.
    Flechon, A.
    Alekseev, B. Y.
    Yu, E. Y.
    Walgren, R. A.
    Russo, F.
    Zimmermann, A. H.
    Bell-Mcguinn, K. M.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
    Weber, J.
    Del Vecchio, M.
    Mandala, M.
    Gogas, H.
    Arance Fernandez, A. M.
    Dalle, S.
    Cowey, C. L.
    Schenker, M.
    Grob, J-J.
    Sileni, V. Chiarion
    Marquez-Rodas, I.
    Butler, M. O.
    Maio, M.
    Middleton, M.
    de la Cruz Merino, L.
    Lobo, M.
    de Pril, V.
    Larkin, J.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S731 - S732
  • [40] Prevalence of Comorbidities with Peanut Allergy: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PALISADE)
    Johnston, Douglas T.
    Sher, Lawrence
    Fineman, Stanley M.
    Griffin, Noelle M.
    Zawadzki, Rezi
    Rosen, Karin
    Siri, Dareen D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB270 - AB270
12345